Literature DB >> 19250685

Harmful effects of anti-zona pellucida antibodies in folliculogenesis, oogenesis, and fertilization.

Giannina Calongos1, Akiko Hasegawa, Shinji Komori, Koji Koyama.   

Abstract

The zona pellucida (ZP) is an extracellular matrix that surrounds the mammalian oocyte and plays an important role in normal folliculogenesis and fertilization. Because of its strong immunogenicity and its possible relation with premature ovarian failure, we conducted the present study to examine whether or not anti-ZP antibodies impaired folliculogenesis. Mouse preantral follicles were cultured with anti-ZP antibodies to evaluate the effects on follicle growth and antral formation. The cultured follicles were also examined by electron microscope and assessed for oocyte maturation, fertilization capacity, and embryo development. The results showed that follicles cultured with anti-ZP antibodies had a smaller diameter than the controls. Also, these antibodies reduced antral formation, mucification, maturation of oocytes (metaphase II), and fertilization rates. Morphologically, ZP thickness was lower in the anti-ZP antibody groups. The quantity of granulosa cell microvillous processes that transverse the ZP was diminished in follicles cultured with anti-ZP antibodies. In conclusion, anti-ZP antibodies were harmful to the normal development of mouse follicles and oocytes in vitro. These antibodies may be a cause of premature ovarian failure syndrome because they disrupt the gap junctions between the oocyte and granulosa cells and, as a consequence, damage the bidirectional communication necessary for normal folliculogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250685     DOI: 10.1016/j.jri.2008.06.003

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  8 in total

Review 1.  Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause.

Authors:  Emanuele Pelosi; Eleanor Simonsick; Antonino Forabosco; Jose Elias Garcia-Ortiz; David Schlessinger
Journal:  Biol Reprod       Date:  2015-04-22       Impact factor: 4.285

Review 2.  Infertility and Immunocontraception based on zona pellucida.

Authors:  Akiko Hasegawa; Hiroyuki Tanaka; Hiroaki Shibahara
Journal:  Reprod Med Biol       Date:  2013-06-29

Review 3.  A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency.

Authors:  A Falorni; V Minarelli; C M Eads; C M Joachim; L Persani; R Rossetti; P Yurttas Beim; V A Pellegrini; P F Schnatz; S Rafique; K Kissell; K A Calis; V Popat; L M Nelson
Journal:  Panminerva Med       Date:  2014-10-07       Impact factor: 5.197

4.  Does ovarian autoimmunity play a role in the pathophysiology of premature ovarian insufficiency?

Authors:  Vrinda Khole
Journal:  J Midlife Health       Date:  2010-01

5.  Serologic autoimmunologic parameters in women with primary ovarian insufficiency.

Authors:  Xiumei Zhen; Jie Qiao; Rong Li; Lina Wang; Ping Liu
Journal:  BMC Immunol       Date:  2014-03-10       Impact factor: 3.615

6.  An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases.

Authors:  Rossella Reggia; Laura Andreoli; Houssni Sebbar; Valentina Canti; Fulvia Ceccarelli; Maria Favaro; Ariela Hoxha; Annalisa Inversetti; Maddalena Larosa; Veronique Ramoni; Roberto Caporali; Fabrizio Conti; Andrea Doria; Carlomaurizio Montecucco; Patrizia Rovere-Querini; Amelia Ruffatti; Guido Valesini; Sonia Zatti; Luca Fallo; Andrea Lojacono; Angela Tincani
Journal:  Rheumatol Adv Pract       Date:  2019-02-22

7.  Screening tests of reproductive immunology in systemic lupus erythematosus.

Authors:  Zdenka Ulcova-Gallova; Alice Mockova; Miroslava Cedikova
Journal:  Autoimmune Dis       Date:  2012-10-24

8.  Molecular adjuvant interleukin-33 enhances the antifertility effect of Lagurus lagurus zona pellucida 3 DNA vaccine administered by the mucosal route.

Authors:  Y X Tu; X P Li; Z Kadir; F C Zhang
Journal:  Braz J Med Biol Res       Date:  2013-12-10       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.